OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress
OneMedNet (NASDAQ:ONMD), a leader in AI-powered Real-World Data (RWD), shared significant achievements in a shareholder letter from CEO Aaron Green. The company has expanded its iRWD™ platform to include five major data marketplaces and grown its network to over 121 million clinical exams across 1,400 healthcare providers.
Key developments include implementing a new subscription-based Data License Agreement model to drive Annual Recurring Revenue, expanding AI-powered de-identification capabilities beyond healthcare into finance, telecom, and retail sectors, and achieving a threefold increase in qualified leads to over 130. The company's datasets meet FDA and international standards, positioning OneMedNet to capture a share of the projected $60-110 billion annual value in pharmaceutical and medical-device sectors through generative AI and RWD.
OneMedNet (NASDAQ:ONMD), leader nei dati reali (RWD) potenziati dall'intelligenza artificiale, ha comunicato importanti risultati in una lettera agli azionisti firmata dal CEO Aaron Green. L'azienda ha ampliato la sua piattaforma iRWD™ includendo cinque principali marketplace di dati e ha esteso la sua rete a oltre 121 milioni di esami clinici distribuiti tra 1.400 fornitori di servizi sanitari.
Tra i principali sviluppi si annoverano l'implementazione di un nuovo modello di accordo di licenza dati basato su abbonamento per incrementare i ricavi ricorrenti annuali, l'espansione delle capacità di de-identificazione basate su AI oltre il settore sanitario verso finanza, telecomunicazioni e retail, e un triplicamento dei lead qualificati che hanno superato quota 130. I dataset dell'azienda rispettano gli standard FDA e internazionali, posizionando OneMedNet per cogliere una quota del valore annuale stimato tra 60 e 110 miliardi di dollari nei settori farmaceutico e dei dispositivi medici tramite l'uso di AI generativa e RWD.
OneMedNet (NASDAQ:ONMD), líder en datos del mundo real (RWD) impulsados por IA, compartió logros significativos en una carta a los accionistas del CEO Aaron Green. La compañía ha ampliado su plataforma iRWD™ para incluir cinco grandes mercados de datos y ha expandido su red a más de 121 millones de exámenes clínicos en 1,400 proveedores de atención médica.
Los desarrollos clave incluyen la implementación de un nuevo modelo de Acuerdo de Licencia de Datos basado en suscripción para impulsar los ingresos anuales recurrentes, la expansión de las capacidades de desidentificación impulsadas por IA más allá de la salud hacia los sectores de finanzas, telecomunicaciones y retail, y un incremento triple en clientes potenciales calificados a más de 130. Los conjuntos de datos de la empresa cumplen con los estándares de la FDA e internacionales, posicionando a OneMedNet para capturar una parte del valor anual proyectado de $60-110 mil millones en los sectores farmacéutico y de dispositivos médicos mediante IA generativa y RWD.
OneMedNet (NASDAQ:ONMD)는 AI 기반 실제 데이터(RWD) 분야의 선두주자로서 CEO 아론 그린이 주주들에게 보낸 서한에서 중요한 성과를 공유했습니다. 회사는 iRWD™ 플랫폼을 다섯 개의 주요 데이터 마켓플레이스로 확장했으며, 1,400개의 의료 제공자와 연계하여 1억 2,100만 건 이상의 임상 검사 네트워크를 구축했습니다.
주요 발전 사항으로는 연간 반복 수익을 창출하기 위한 구독 기반 데이터 라이선스 계약 모델 도입, 의료 분야를 넘어 금융, 통신, 소매 부문까지 AI 기반 익명화 기능 확장, 그리고 자격을 갖춘 리드가 세 배 증가하여 130건 이상을 달성한 점이 있습니다. 회사의 데이터셋은 FDA 및 국제 기준을 충족하여 OneMedNet이 생성 AI와 RWD를 통해 제약 및 의료기기 분야에서 연간 600억~1,100억 달러 규모의 가치를 확보할 수 있는 위치에 있습니다.
OneMedNet (NASDAQ:ONMD), leader dans les données du monde réel (RWD) alimentées par l'IA, a partagé des réalisations importantes dans une lettre aux actionnaires du PDG Aaron Green. L'entreprise a élargi sa plateforme iRWD™ pour inclure cinq grands marchés de données et a étendu son réseau à plus de 121 millions d'examens cliniques auprès de 1 400 prestataires de soins de santé.
Les développements clés comprennent la mise en place d'un nouveau modèle d'accord de licence de données basé sur un abonnement pour stimuler les revenus annuels récurrents, l'expansion des capacités de dé-identification alimentées par l'IA au-delà du secteur de la santé vers la finance, les télécommunications et le commerce de détail, et une augmentation par trois du nombre de prospects qualifiés à plus de 130. Les ensembles de données de l'entreprise respectent les normes de la FDA et internationales, positionnant OneMedNet pour capter une part de la valeur annuelle projetée entre 60 et 110 milliards de dollars dans les secteurs pharmaceutique et des dispositifs médicaux grâce à l'IA générative et aux RWD.
OneMedNet (NASDAQ:ONMD), ein führendes Unternehmen für KI-gestützte Real-World-Daten (RWD), teilte bedeutende Erfolge in einem Aktionärsschreiben des CEO Aaron Green mit. Das Unternehmen hat seine iRWD™-Plattform auf fünf große Datenmarktplätze erweitert und sein Netzwerk auf über 121 Millionen klinische Untersuchungen bei 1.400 Gesundheitsdienstleistern ausgebaut.
Zu den wichtigsten Entwicklungen gehören die Einführung eines neuen abonnementbasierten Datenlizenzvertragsmodells zur Steigerung der jährlichen wiederkehrenden Einnahmen, die Erweiterung der KI-gestützten De-Identifizierungsfunktionen über das Gesundheitswesen hinaus auf die Bereiche Finanzen, Telekommunikation und Einzelhandel sowie eine Verdreifachung qualifizierter Leads auf über 130. Die Datensätze des Unternehmens erfüllen FDA- und internationale Standards, was OneMedNet in eine Position bringt, um einen Anteil am prognostizierten jährlichen Wert von 60 bis 110 Milliarden US-Dollar in den Pharma- und Medizinproduktebranchen durch generative KI und RWD zu sichern.
- Network expansion to over 1,400 hospital sites with 121 million clinical exams, growing 5% annually
- Strategic partnerships with 5 major data marketplaces including AWS, Protege AI, Bayer, Datavant, and HealthVerity
- Implementation of subscription-based pricing model to drive recurring revenue
- 300% increase in qualified leads compared to previous years
- Regulatory compliance with FDA and international standards for real-world evidence
- AI-powered platform expansion beyond healthcare into finance, telecom, and retail sectors
- Stock price performance not reflecting company's potential according to CEO
- Highly competitive market with projected 36% CAGR through 2030 requiring continuous innovation
Insights
OneMedNet strengthens its position in healthcare data with expanded partnerships, 121M+ clinical exams in network, and AI-driven de-identification capabilities across multiple industries.
This shareholder letter outlines significant progress for OneMedNet's AI-powered Real-World Data (RWD) business. The company has effectively expanded its network to include five major data marketplaces including Amazon Data Exchange, Protege AI, Bayer Data Marketplace, Datavant, and HealthVerity. This marketplace diversification creates multiple revenue channels and expands their potential customer base substantially.
The company now has access to over 121 million clinical exams through partnerships with 1,400+ healthcare providers, with organic growth continuing at approximately
Most notably, OneMedNet has evolved beyond simply providing healthcare data to developing AI-powered anonymization technology applicable across multiple industries including finance, telecom, and retail. This represents a significant expansion of their addressable market beyond healthcare. Their iRWD™ platform's ability to search, de-identify and curate datasets at scale addresses critical privacy compliance requirements that are increasingly stringent across regulated industries.
The company's transition to a subscription-based Data License Agreement (DLA) model is strategically important for building predictable Annual Recurring Revenue (ARR). This shift from one-time sales to recurring licenses matches current SaaS investor preferences and typically commands higher valuation multiples if successful. The revenue-sharing model with healthcare partners creates aligned incentives for network expansion.
While the letter highlights impressive progress, it lacks specific financial metrics - there's no mention of current revenue, growth rates, margins, or path to profitability. The
MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced today that Aaron Green, President and CEO, issued the following letter to shareholders and other stakeholders of the Company:
Dear OneMedNet Shareholders, Partners, and Family,
Following a year of significant progress, OneMedNet is navigating 2025 with strong momentum, making substantial strides in expanding our market presence, enhancing our Real-World Data platform, and developing an AI driven tool set to anonymize and De-identify data across multiple industries. My leadership team and I feel it is important that you know our key achievements, including onboarding five major data marketplaces, surpassing 121 million clinical exams in our network, and charting the path forward as we capitalize on the growing demand for de-identified data starting with regulatory-grade RWD.
We are excited about OneMedNet’s scalable, tech-enabled model that positions us for sustained growth and long-term value creation.
2024 Highlights
- AI-Powered Platform: Our federated iRWD™ platform leverages cost-effective AI tools to search, de-identify, and curate precise datasets at scale. These tools serve healthcare as well as industries like finance, telecom, and retail through advanced anonymization technology.
- Expanded Market Reach: We are now partnered with five leading data marketplaces—Amazon Data Exchange (AWS), Protege AI, Bayer Data Marketplace, Datavant, and HealthVerity. These platforms collectively span multiple segments of the healthcare data ecosystem, including real-world evidence, clinical trial optimization, payer-provider data exchange, and AI model training. From AWS’s enterprise-scale infrastructure to Datavant and HealthVerity’s leadership in de-identified health data, and Protege AI’s focus on model-ready datasets, they form a powerful network supporting innovation across life sciences, pharma, and digital health.
- Network Growth: Our partnerships with over 1,400 hospital and healthcare provider sites have grown our medical imaging-rich RWD repository to over 121 million clinical exams, expanding organically by ~
5% annually through daily patient care activities. - Amplified Brand Presence: Increased participation in industry trade shows and targeted campaigns has strengthened stakeholder engagement, with imaging’s role in longitudinal patient records resonating as a key differentiator. This momentum generated over 130 qualified leads—a threefold increase from previous years—demonstrating rising market interest. The growing demand for these services is further evidenced by many customers consistently returning to OneMedNet first for their data needs, driven by their positive experiences with our platform, quality data and services.
- Diverse Customer Base: Our healthcare regulatory-grade datasets are licensed by leading life sciences organizations for clinical trials, regulatory submissions, and AI model development, reflecting strong market validation.
- Regulatory Compliance: Our datasets meet stringent FDA and international standards, enabling real-world evidence (RWE) for submissions, post-market surveillance, and research.
- AI Innovation: We provide foundational data to train and validate AI models in medical imaging and diagnostics, accelerating advancements in precision medicine.
What Sets Us Apart
OneMedNet does not just collect raw data. We deliver:
- AI-assisted de-identification and anonymization, applicable across industries like healthcare, finance, telecom, and retail.
- OneMedNet delivers premium, purpose-built RWD, not raw data.
- Curated, regulatory-grade datasets
- Longitudinal tracking across multiple care events.
- Imaging-centric iRWD™, enhanced by custom cohort matching and AI-powered refinement.
- High customer satisfaction, driving repeat orders from leading life sciences organizations.
The Opportunity Ahead
The need for RWD has never been greater. The traditional model of running lengthy, expensive clinical trials is being disrupted. Regulators like the FDA and European Medicines Agency (EMA) are increasingly encouraging the use of RWE as part of the approval process.
According to McKinsey generative AI and RWD could unlock
Subscription-Based pricing model
We have added a subscription-based Data License Agreement (DLA) structure to drive Annual Recurring Revenue (ARR). Our platform now supports near real-time data updates, allowing access to curated, regulatory-grade datasets through flexible, recurring licenses. This enhances scalability, strengthens network effects, and aligns with long-term demand for high-quality RWD. Our partner hospitals and clinics share the revenue, incentivizing network expansion and data depth.
Looking Forward
Our three pillars—Platform, Partners, and People—anchor our strategy. Our proven AI de-identification and anonymization across industries, iRWD™ platform, growing network of provider sites, and experienced leadership team, with expertise in AI, cloud solutions, healthcare, regulatory compliance, and M&A, are aligned for execution. We are intensifying investor outreach and communication to highlight our progress and vision.
To our shareholders: Thank you for your support. While stock price fluctuations may not reflect our full potential, we are building enduring value through data, scalability, and relevance to the future of healthcare and beyond.
Sincerely,
Aaron Green
President and CEO
OneMedNet Corporation
Investor Relations - https://www.onemednet.com/investor-relations/
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
What are OneMedNet's (ONMD) main achievements in 2024?
How is OneMedNet (ONMD) generating recurring revenue?
What is the market opportunity for OneMedNet's (ONMD) RWD platform?
How many healthcare providers are in OneMedNet's (ONMD) network?
What industries does OneMedNet's (ONMD) AI platform serve?
